-transparent.png){kind=logo}
Phosphonoformate, an inhibitor of reverse transcriptase in a number of retroviruses, was shown to have a dose-related inhibitory effect on human T-cell lymphotropic virus type III (HTLV-III) replication in the H9 cell line in vitro. HTLV-III replication was eliminated at a concentration of 680 mumol, a non-cytotoxic dose. A lower dose of 132 mumol inhibited HTLV-III replication by more than 98%, as measured by reverse transcriptase activity, compared with untreated infected cultures. Reverse transcriptase activity in HTLV-III particles was completely inhibited by 5.0 mumol phosphonoformate.
Related Publications
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
July 1986,
Antimicrobial agents and chemotherapy,
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
June 1986,
Journal of clinical microbiology,
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
January 1987,
Hematologic pathology,
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
September 1985,
Lancet (London, England),
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
December 1986,
Antimicrobial agents and chemotherapy,
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
December 1985,
Annals of internal medicine,
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
August 2008,
Antimicrobial agents and chemotherapy,
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
May 1986,
The Journal of clinical investigation,
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
August 1987,
The Journal of clinical investigation,
E G Sandstrom, and
J C Kaplan, and
R E Byington, and
M S Hirsch
January 1986,
Transfusion,
